Is there a future for gene therapy? (Q33603980)

28 July 2017

1 reference

title

Is there a future for gene therapy? (English)

1 reference

28 July 2017

0 references

Howell JM

1 reference

28 July 2017

publication date

1 March 1999

1 reference

28 July 2017

published in

Neuromuscular Disorders

1 reference

28 July 2017

1 reference

28 July 2017

1 reference

28 July 2017

page(s)

102-107

1 reference

The scope of gene therapy in humans: scientific, safety and ethical considerations

28 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0960-8966%2898%2900102-3

7 January 2021

Naked DNA transport and expression in mammalian cells

1 reference

https://api.crossref.org/works/10.1016%2FS0960-8966%2898%2900102-3

7 January 2021

Human gene marker/therapy clinical protocols

1 reference

https://api.crossref.org/works/10.1016%2FS0960-8966%2898%2900102-3

7 January 2021

Direct gene transfer into mouse muscle in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0960-8966%2898%2900102-3

7 January 2021

Human dystrophin expression in mdx mice after intramuscular injection of DNA constructs

1 reference

https://api.crossref.org/works/10.1016%2FS0960-8966%2898%2900102-3

7 January 2021

Dystrophin expression in muscles of mdx mice after adenovirus-mediated in vivo gene transfer

1 reference

https://api.crossref.org/works/10.1016%2FS0960-8966%2898%2900102-3

7 January 2021

Use of the dog model for Duchenne muscular dystrophy in gene therapy trials.

1 reference

https://api.crossref.org/works/10.1016%2FS0960-8966%2898%2900102-3

7 January 2021

Direct dystrophin and reporter gene transfer into dog muscle in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0960-8966%2898%2900102-3

7 January 2021

High-level dystrophin expression after adenovirus-mediated dystrophin minigene transfer to skeletal muscle of dystrophic dogs: prolongation of expression with immunosuppression.

1 reference

https://api.crossref.org/works/10.1016%2FS0960-8966%2898%2900102-3

7 January 2021

Implications of maturation for viral gene delivery to skeletal muscle

1 reference

https://api.crossref.org/works/10.1016%2FS0960-8966%2898%2900102-3

7 January 2021

Problems and potential for gene therapy in Duchenne muscular dystrophy

1 reference

https://api.crossref.org/works/10.1016%2FS0960-8966%2898%2900102-3

7 January 2021

Production and Characterization of Improved Adenovirus Vectors with the E1, E2b, and E3 Genes Deleted

1 reference

https://api.crossref.org/works/10.1016%2FS0960-8966%2898%2900102-3

7 January 2021

Insertion of the adenoviral E3 region into a recombinant viral vector prevents antiviral humoral and cellular immune responses and permits long-term gene expression

1 reference

https://api.crossref.org/works/10.1016%2FS0960-8966%2898%2900102-3

7 January 2021

Strategies to accomplish targeted gene delivery to muscle cells employing tropism-modified adenoviral vectors

1 reference

https://api.crossref.org/works/10.1016%2FS0960-8966%2898%2900102-3

7 January 2021

Direct intramuscular injection with recombinant AAV vectors results in sustained expression in a dog model of hemophilia

1 reference

https://api.crossref.org/works/10.1016%2FS0960-8966%2898%2900102-3

7 January 2021

Sustained expression of genes delivered directly into liver and muscle by lentiviral vectors

1 reference

https://api.crossref.org/works/10.1016%2FS0960-8966%2898%2900102-3

7 January 2021

Selection and use of ligands for receptor-mediated gene delivery to myogenic cells

1 reference

https://api.crossref.org/works/10.1016%2FS0960-8966%2898%2900102-3

7 January 2021

De Novo Protein Design: Fully Automated Sequence Selection

1 reference

https://api.crossref.org/works/10.1016%2FS0960-8966%2898%2900102-3

7 January 2021

Lipoadenofection-mediated gene delivery to the corneal endothelium: prospects for modulating graft rejection

1 reference

https://api.crossref.org/works/10.1016%2FS0960-8966%2898%2900102-3

7 January 2021

Amelioration of collagen-induced arthritis by CD95 (Apo-1/Fas)-ligand gene transfer.

1 reference

https://api.crossref.org/works/10.1016%2FS0960-8966%2898%2900102-3

7 January 2021

Skeletal and Cardiac Myopathies in Mice Lacking Utrophin and Dystrophin: A Model for Duchenne Muscular Dystrophy

1 reference

https://api.crossref.org/works/10.1016%2FS0960-8966%2898%2900102-3

7 January 2021

Utrophin-dystrophin-deficient mice as a model for Duchenne muscular dystrophy

1 reference

https://api.crossref.org/works/10.1016%2FS0960-8966%2898%2900102-3

7 January 2021

Expression of truncated utrophin leads to major functional improvements in dystrophin-deficient muscles of mice

1 reference

https://api.crossref.org/works/10.1016%2FS0960-8966%2898%2900102-3

7 January 2021

Utrophin muscles in on the action

1 reference

https://api.crossref.org/works/10.1016%2FS0960-8966%2898%2900102-3

7 January 2021

Prevalence of dystrophin-positive fibers in 85 Duchenne muscular dystrophy patients

1 reference

https://api.crossref.org/works/10.1016%2FS0960-8966%2898%2900102-3

7 January 2021

A FUNCTIONAL DISORDER OF MUSCLE ASSOCIATED WITH THE ABSENCE OF PHOSPHORYLASE.

1 reference

https://api.crossref.org/works/10.1016%2FS0960-8966%2898%2900102-3

7 January 2021

Hereditary absence of muscle phosphorylase (McArdle's syndrome)

1 reference

https://api.crossref.org/works/10.1016%2FS0960-8966%2898%2900102-3

7 January 2021

Studies on the expression and evolution of the glycogen phosphorylase gene family in the rat

1 reference

https://api.crossref.org/works/10.1016%2FS0960-8966%2898%2900102-3

7 January 2021

A splice-site mutation causing ovine McArdle's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0960-8966%2898%2900102-3

7 January 2021

10.1016/S0960-8966(98)00102-3

Identifiers

DOI

1 reference

28 July 2017

1 reference